By Mill Chart
Last update: Jan 30, 2024
JOHNSON & JOHNSON (NYSE:JNJ) has caught the attention of dividend investors as a stock worth considering. NYSE:JNJ excels in profitability, solvency, and liquidity, all while providing a decent dividend. Let's delve into the details.
An integral part of ChartMill's stock analysis is the Dividend Rating, which spans from 0 to 10. This rating evaluates diverse dividend factors, including yield, historical data, growth, and sustainability. NYSE:JNJ has received a 7 out of 10:
ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NYSE:JNJ, the assigned 6 reflects its health status:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NYSE:JNJ, the assigned 7 is a significant indicator of profitability:
Our Best Dividend screener lists more Best Dividend stocks and is updated daily.
Our latest full fundamental report of JNJ contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
JOHNSON & JOHNSON
NYSE:JNJ (4/19/2024, 7:04:00 PM)
After market: 147.89 -0.02 (-0.01%)147.91
+2.17 (+1.49%)
As uncertainty in the global economy and geopolitical climate abounds, investors should focus on stocks with proven track records.
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game.
The Nasdaq and S&P 500 tumbled below their 50-day lines.
This is what could happen next to Johnson & Johnson shares.
NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and Textron are included in this Analyst Blog.
A Florida jury on Thursday concluded that Johnson & Johnson's baby powder talc product did not cause the ovarian cancer of a Florida woman who died in 2019. The lawsuit was brought by family members of Patricia Matthey, a Sarasota County resident who used Johnson's baby powder daily from 1965 until August 2016, when she was diagnosed with ovarian cancer, according to her family's lawsuit. J&J's Worldwide Vice President of Litigation Erik Haas said the company was vindicated by the jury's decision.
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ).
Discover recession-proof stocks that thrive amid economic uncertainty, offering stability and consistent growth.
Investors wondering which tax refund stocks to invest in should consider these names, each of which is a capital compounder.
Top S&P500 movers in Thursday's after hours session
Balancing Dividends and Fundamentals: The Case of JOHNSON & JOHNSON (NYSE:JNJ).